Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-12-14Clinical Trial Update: Quetiapine and the Dopaminergic Epigenetic Control [Phase 4]
Phase 4 clinical trial update on quetiapine focusing on dopaminergic epigenetic control in schizophrenia.
-
FDA approval · 2020-12-10FDA Approved: ASENAPINE — Original Application (Alembic Pharmaceuticals Limited)
The FDA approved Alembic Pharmaceuticals Limited's original ANDA for asenapine, enabling a generic version of the drug to be marketed.
-
FDA approval · 2020-12-10FDA Approved: ASENAPINE — Original Application (Sigmapharm Laboratories, LLC)
FDA approved Sigmapharm Laboratories, LLC's original (ANDA) application for asenapine, enabling a generic version to enter the market. The a…
-
FDA approval · 2020-12-10FDA Approved: ASENAPINE — Original Application (Breckenridge Pharmaceutical, Inc.)
FDA approved Breckenridge Pharmaceutical's original application for a generic asenapine maleate product. The generic is intended for the sam…
-
CLINICAL_TRIALS trial_result · 2020-11-27Clinical Trial Update: Improving Negative Symptoms of Psychosis In Real-world Environments [NA]
A completed clinical trial evaluating strategies to improve negative symptoms of schizophrenia in real-world environments; results posted in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in Schizophrenia [NA]
Completed clinical trial investigating non-invasive brain stimulation to engage prefrontal cortex in schizophrenia/psychosis; results posted…
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Antipsychotic Induced Structural and Functional Brain Changes [Phase 4]
Phase 4 clinical trial update on antipsychotic-induced structural and functional brain changes in schizophrenia; study terminated.
-
CLINICAL_TRIALS trial_result · 2020-11-23Clinical Trial Update: Study of Efficacy of PEAR-004 in Schizophrenia [Phase 2]
Phase 2 trial update for PEAR-004 in schizophrenia; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-19Clinical Trial Update: Long-term Study of DSP-5423P in Patients With Schizophrenia [Phase 3]
Phase 3 long-term study of DSP-5423P in schizophrenia has completed with results posted.
-
FDA approval · 2020-11-17FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Patriot Pharmaceuticals LLC)
The FDA approved a supplemental application for HALOPERIDOL DECANOATE by Patriot Pharmaceuticals LLC, indicating an approved change to the p…
-
FDA approval · 2020-11-17FDA Approved: RISPERIDONE — Supplemental Application (Solco Healthcare US, LLC)
The FDA approved Solco Healthcare US, LLC's supplemental application to market a generic risperidone product.
-
CLINICAL_TRIALS trial_result · 2020-11-17Clinical Trial Update: Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics [Phase 4]
Phase 4 trial comparing a long-acting injectable antipsychotic to clinician's choice early in treatment for schizophrenia; results posted af…
-
FDA approval · 2020-11-16FDA Approved: OLANZAPINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Teva Pharmaceuticals' olanzapine product under an ANDA.
-
FDA approval · 2020-11-09FDA Approved: OLANZAPINE — Supplemental Application (Dr. Reddy's Laboratories Ltd.)
FDA approved a supplemental application for olanzapine from Dr. Reddy's Laboratories, establishing a generic version of the drug. The action…
-
FDA approval · 2020-11-09FDA Approved: OLANZAPINE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
The FDA approved a supplemental application for olanzapine filed by Dr. Reddy's Laboratories Inc., indicating regulatory approval related to…
-
CLINICAL_TRIALS trial_result · 2020-11-09Clinical Trial Update: Linagliptin and Mesenchymal Stem Cells: A Pilot Study [Phase 4]
A Phase 4 pilot study investigating linagliptin in combination with mesenchymal stem cells for schizophrenia has been completed.
-
CLINICAL_TRIALS trial_result · 2020-11-09Clinical Trial Update: Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness [NA]
Clinical trial update on a mobile texting intervention for people with serious mental illness has completed with posted results.
-
FDA approval · 2020-10-30FDA Approved: PALIPERIDONE — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for paliperidone (generic) submitted by NorthStar RxLLC.
-
FDA approval · 2020-10-30FDA Approved: QUETIAPINE EXTENDED RELEASE — Supplemental Application (ACI Healthcare USA, Inc.)
FDA approves a supplemental application for a generic quetiapine extended-release product by ACI Healthcare USA, Inc.
-
CLINICAL_TRIALS trial_result · 2020-10-30Clinical Trial Update: Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Results [NA]
A terminated clinical trial evaluating bilateral repetitive transcranial magnetic stimulation for auditory hallucinations in schizophrenia w…
-
FDA approval · 2020-10-29FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC.
-
FDA approval · 2020-10-28FDA Approved: RISPERIDONE — Supplemental Application (Natco Pharma USA LLC)
The FDA approved a supplemental application for Risperidone from Natco Pharma USA LLC under an ANDA.
-
CLINICAL_TRIALS trial_result · 2020-10-27Clinical Trial Update: A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication [Phase 2]
Phase 2 study assessing ASP4345 as add-on treatment for cognitive impairment in schizophrenia on stable doses of antipsychotic medication. T…
-
CLINICAL_TRIALS trial_result · 2020-10-26Clinical Trial Update: Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia [Phase 3]
Phase 3 trial update on flexible-dose, long-term safety of Lu AF35700 in adults with schizophrenia; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2020-10-26Clinical Trial Update: The Use of Transcranial Electrical Stimulation for Hallucinations [NA]
A terminated clinical trial investigating transcranial electrical stimulation for schizophrenia, with results posted in 2020.